BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 34791710)

  • 1. Radiologic-pathologic association of tumor-like lesions with inflammation in cerebral white matter: Comparison of two cases with distinct clinical outcomes.
    Shishido-Hara Y; Akazawa K; Takeuchi H; Hirato J; Konishi E; Yamada K; Itoh K; Hashimoto N
    Neuropathology; 2021 Dec; 41(6):468-475. PubMed ID: 34791710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria.
    Tesileanu CMS; Dirven L; Wijnenga MMJ; Koekkoek JAF; Vincent AJPE; Dubbink HJ; Atmodimedjo PN; Kros JM; van Duinen SG; Smits M; Taphoorn MJB; French PJ; van den Bent MJ
    Neuro Oncol; 2020 Apr; 22(4):515-523. PubMed ID: 31637414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A juvenile case of epilepsy-associated, isocitrate dehydrogenase wild-type/histone 3 wild-type diffuse glioma with a rare BRAF
    Sadashima S; Suzuki SO; Haruyama H; Mukae N; Fujioka Y; Hata N; Mizoguchi M; Ishimatsu K; Hiwatashi A; Iwaki T
    Neuropathology; 2020 Dec; 40(6):646-650. PubMed ID: 32996219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?
    Barresi V; Lionti S; Valori L; Gallina G; Caffo M; Rossi S
    J Neuropathol Exp Neurol; 2017 May; 76(5):342-346. PubMed ID: 28419269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours.
    Wasserman JK; Nicholas G; Yaworski R; Wasserman AM; Woulfe JM; Jansen GH; Chakraborty S; Nguyen TB
    PLoS One; 2015; 10(4):e0123890. PubMed ID: 25849605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
    Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
    Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience.
    Molica C; Gili A; Nardelli C; Pierini T; Arniani S; Beacci D; Mavridou E; Mandarano M; Corinaldesi R; Metro G; Gorello P; Giovenali P; Cenci N; Castrioto C; Lupattelli M; Roila F; Mecucci C; La Starza R
    Sci Rep; 2023 Nov; 13(1):20101. PubMed ID: 37973912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Performance of [
    Nakajo K; Uda T; Kawashima T; Terakawa Y; Ishibashi K; Tsuyuguchi N; Tanoue Y; Nagahama A; Uda H; Koh S; Sasaki T; Ohata K; Kanemura Y; Goto T
    World Neurosurg; 2021 Apr; 148():e471-e481. PubMed ID: 33444827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A
    Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse astrocytic glioma, IDH-Wildtype, with molecular features of glioblastoma, WHO grade IV: A single-institution case series and review.
    Lee D; Riestenberg RA; Haskell-Mendoza A; Bloch O
    J Neurooncol; 2021 Mar; 152(1):89-98. PubMed ID: 33389563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma.
    Vizcaino MA; Palsgrove DN; Yuan M; Giannini C; Cabrera-Aldana EE; Pallavajjala A; Burger PC; Rodriguez FJ
    Brain Pathol; 2019 Mar; 29(2):193-204. PubMed ID: 30222900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligodendroglioma showing pleomorphic xanthoastrocytoma-like perivascular microlesion: With IDH1, TERT promoter mutation and 1p/19q codeletion detected in both components.
    Murakami C; Ikota H; Nobusawa S; Nakata S; Yamazaki T; Hashiba Y; Hirato J; Yokoo H
    Pathol Int; 2020 Jan; 70(1):40-46. PubMed ID: 31855307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid progression of an IDH-wild type histological low-grade glioma harbouring TERT promoter mutation and diffuse CD34 expression: a case report.
    Wang H; Tan C; Xu T; Li W
    Folia Neuropathol; 2021; 59(1):104-111. PubMed ID: 33969682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
    Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
    Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
    Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
    J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.
    Kuwahara K; Ohba S; Nakae S; Hattori N; Pareira ES; Yamada S; Sasaki H; Abe M; Hasegawa M; Hirose Y
    Brain Tumor Pathol; 2019 Oct; 36(4):135-143. PubMed ID: 31324999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.